Who Paid My Doc
Joseph Wolcott
Undersea and Hyperbaric Medicine Lubbock, TX Medical Doctor
NPI 1114119872 CMS profile 50419
2002 Oxford Ave, Lubbock, TX 79410
General payments
$38,261
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Joseph Wolcott of Lubbock, TX is reported in the CMS Open Payments database as having received $38,261 across 313 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,263 | 16 | |
| 2024 | General | $5,207 | 30 | |
| 2023 | General | $5,421 | 31 | |
| 2022 | General | $5,732 | 52 | |
| 2021 | General | $5,685 | 59 | |
| 2020 | General | $5,477 | 60 | |
| 2019 | General | $5,476 | 65 |
Beside peers
- Joseph Wolcott
- Undersea and Hyperbaric Medicine median
- Middle half of Undersea and Hyperbaric Medicine
- National median
In program year 2025, general payments to Joseph Wolcott were reported at $5,263. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.
Show as a table
| Year | Joseph Wolcott | Undersea and Hyperbaric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,476 | $201 | $85–$538 | $163 |
| 2020 | $5,477 | $84 | $31–$222 | $114 |
| 2021 | $5,685 | $138 | $52–$383 | $132 |
| 2022 | $5,732 | $135 | $51–$385 | $149 |
| 2023 | $5,421 | $143 | $75–$442 | $160 |
| 2024 | $5,207 | $178 | $80–$442 | $164 |
| 2025 | $5,263 | $208 | $52–$518 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
1,571
Drug cost
$130,920
Branded share of claims
35.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Daptomycin | Generic | 79 | $65,734 | |
| Santyl Collagenase Clostridium Hist. | Brand | 22 | $21,466 | |
| Ertapenem Ertapenem Sodium | Brand | 33 | $14,125 | |
| Linezolid | Generic | 66 | $4,728 | |
| Doxycycline Hyclate | Generic | 366 | $4,494 | |
| Piperacillin-Tazobactam Piperacillin Sodium/Tazobactam | Brand | 35 | $4,356 | |
| Meropenem | Generic | 23 | $4,088 | |
| Cefepime Hcl | Generic | 46 | $3,566 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 180 | $2,141 | |
| Triamcinolone Acetonide | Generic | 72 | $1,220 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Billing to Medicare
Part B · data year 2024 · 82 billing codesPaid by Medicare
$4,358,722
Medicare patients
603
Services billed
75,406
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Diabetes | 51% | |
| Ischemic heart disease | 41% | |
| Chronic kidney disease | 36% | |
| Heart failure | 31% | |
| Atrial fibrillation | 29% | |
| Depression | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Grafix plus, per square centimeter Q4304 | Office | 14 | 630 | $651,532 |
| Palingen or palingen xplus, per square centimeter Q4173 | Office | 18 | 1,352 | $414,851 |
| Injection, oritavancin (kimyrsa), 10 mg J2406 | Office | 43 | 8,880 | $275,768 |
| Dual layer impax membrane, per square centimeter Q4262 | Office | 12 | 286 | $158,475 |
| Injection, dalbavancin, 5 mg J0875 | Office | 15 | 7,700 | $92,567 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 13 | 88 | $31 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| NUZYRA |
|
$79 | — | — |
| Kimyrsa |
|
$18 | — | 8,880 |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
313 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Undersea and Hyperbaric Medicine in Texas
Wade Farrow
Undersea and Hyperbaric Medicine · College Station, TX
Heather Aguirre
Undersea and Hyperbaric Medicine · San Antonio, TX
Andrew Applewhite
Undersea and Hyperbaric Medicine · Dallas, TX
Noel Oliveira
Undersea and Hyperbaric Medicine · Edinburg, TX
Jayesh Shah
Undersea and Hyperbaric Medicine · San Antonio, TX
Marcus Gitterle
Undersea and Hyperbaric Medicine · New Braunfels, TX
Related records
Undersea and Hyperbaric Medicine in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Undersea and Hyperbaric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.